Background In the absence of sufficient data directly comparing multiple treatments, indirect comparisons using network meta-analyses (NMAs) can provide useful information. Under current contrast-based (CB) methods for binary outcomes, the patient-centered measures including the treatment-specific event rates and risk differences (RDs) are not provided, which may create some unnecessary obstacles for patients to comprehensively trade-off efficacy and safety measures.
Introduction
Comparative effectiveness research (CER) relies on accurate assessment of treatment efficacy and safety to provide evidence to inform health-care decisions that then may need to be tailored to a specific patient. The growth of interest in evidence-based medicine has led to a dramatic increase in attention paid to systematic reviews and meta-analyses [1, 2] . In order to account for the growing number of treatment comparisons of interest for a given condition, methods for network meta-analysis (NMA) (also called mixed or multiple treatment comparisons) which expand the scope of conventional pairwise meta-analyses have been developed. NMA simultaneously synthesizes both direct comparisons of interventions within randomized controlled trials (RCTs) and indirect comparisons across trials. In the simplest case, one may be interested in comparing two treatments A and C. Direct evidence can only be obtained from RCTs of A versus C, while indirect evidence can be obtained from RCTs of either A or C versus a common comparator B [3] . When both direct and indirect evidences are available, the two sources of information can be combined as a weighted average using appropriate statistical methods. With appropriate assumptions, borrowing strength from indirect evidence allows more precise estimates of treatment differences than can be obtained from pairwise meta-analysis [4] .
A limitation of reporting for many current NMA methods for binary outcomes is that the only summary statistic usually reported is the odds ratio (OR) [5] [6] [7] [8] [9] [10] [11] [12] [13] . Although it is well known that risk ratios (RRs) and ORs diverge when events are common (i.e., event rates are higher than 10%) [14] [15] [16] [17] , ORs are often mistakenly thought as RRs by physicians, patients, and their care givers. Absolute measures including treatment-specific event rates and risk differences (RDs) contain important information that cannot be expressed by ORs [18] . Thus, both relative measures and absolute measures should be reported and reporting only OR is not proper. However, to the best of our knowledge, only a few published NMAs [19, 20] . have reported RR, but none have reported the treatment-specific event rates and RDs. This limitation in reporting arises because many current statistical approaches and software [21] [22] [23] [24] [25] [26] [27] [28] [29] are not capable of estimating treatment-specific response proportions and summary statistics such as the RD and RR. They focus on treatment contrasts where one of the arms of each study is chosen as 'baseline'. Since many NMAs do not have a common 'control' arm such as a 'placebo' or 'standard' intervention and different trials may have different 'baselines', specifying a common distribution for 'baseline' groups is generally not interpretable. Thus, many current NMA methods treat the underlying 'baseline' risks as nuisance parameters and therefore fail to estimate the treatment-specific response proportions. Although a few [25, [30] [31] [32] [33] discussed the transformation from the ORs to RRs and RDs, they depend on a strong assumption that either the event rate in a 'reference' treatment group can be accurately estimated from some external data, or by summarizing only trials with the 'reference' arm with a separate (random effects) model. In many cases, such external data are not available limiting the applicability of the former approach. In addition, even if some external data are available, it may come from a different population than what the NMA may represent. From the theory of missing data analysis [34] , the latter approach is unbiased only under a strong assumption of missing completely at random (MCAR; that is, all trials randomly choose to include or not include treatment arms). Furthermore, it is less statistically efficient and the back-transformed RRs and RDs can be noticeably different if a different treatment arm is chosen as the 'reference' group even with exactly the same model and priors.
To address this issue, we developed a novel multivariate Bayesian hierarchical model from the perspective of missing data analysis. We compare our approach to other alternative methods using two hypothetical NMA data sets and then re-analyze two published NMAs in which the ORs are the only effect measures reported to illustrate potential differences.
Methods
Let us consider a NMA with a collection of studies i = 1, 2, . . . , I, and each of the studies only reports on a subset of the complete collection of K treatments. Let k i be the number of treatments and S i be the set of treatments that are compared in study i. Studies with k i .2 are called 'multi-arm' studies, in contrast to k i = 2 for 'two-arm' studies. Let D i = f(y ik , n ik ), k 2 S i g denote the available data from the ith trial, where n ik is the total number of subjects and y ik is the total number of successes for the kth treatment in the ith study. We then denote the corresponding probability of success by p ik . In this section, we first briefly review the most commonly used contrast-based (CB) approach, then present our novel arm-based (AB) approach illustrating how to accurately estimate the overall treatment-specific event rates from the perspective of missing data analysis. Finally, we evaluate the performance of a few alternative methods using two hypothetical examples.
The CB approach
Let b i be the specified 'baseline' treatment for the ith trial, commonly denoted as b for simplicity. Let
The most commonly used CB models use the following Bayesian hierarchical model [25, 35] y ik ;Bin(n ik , p ik ), k 2 S i , i = 1, . . . , I ð2:1Þ
Network meta-analysis of randomized clinical trials 247
Some prior distributions are then chosen for m i , d bk , s 2 bk , and g (b) hk . As many NMAs do not have a common 'baseline' and different 'baselines' are needed for different trials, the 'baseline' effect m i is treated as nuisance parameter and specifying a common distribution for m i is generally not interpretable. As a consequence, unless a strong assumption that the overall event rate of a 'reference' group is either available based on some external data or can be unbiasedly estimated by summarizing only trials with the 'reference' arm by a separate (random effects) model, current CB based approach is not able to estimate the overall treatment-specific event rates, RRs, and RDs.
The AB approach
We view the analytic challenges associated with NMA from the perspective of missing data analysis [34] [35] [36] [37] [38] . The basic idea of this 'arm-based' approaches to NMA (which focus on modeling the event proportions for each treatment arm), in contrast to the 'contrastbased' approaches (which focus on modeling the relative treatment effects, for example, ORs, comparing treatments), has been briefly discussed by Salanti et al. [39, 40] , but thoroughly not from the missing data perspective. When viewed from this perspective, the proportion of patients responding to each treatment and associated marginal summary statistics such as the RD, RR, and OR can be estimated. Specifically, we assume that each study hypothetically compares all treatments, many of which are missing by design and thus can be considered as missing at random (MAR) [35] .
Specifically, we consider the multivariate Bayesian hierarchical mixed model (MBHMM), which extends the bivariate generalized linear mixed model for the meta-analysis of comparative studies of two arms [41] . First, we assume conditional on P i = fp ik g, the elements y ik of Y i = fy ik g are independently binomially distributed with probability mass function
Second, we assume a multivariate normal distribution (MVN) for fp ik g on a probit transformed scale.
In the absence of any individual-level covariates, the model is specified as
where F() is the standard normal cumulative distribution function, (m 1 , . . . , m K ) are treatment-specific fixed effects, R K is a positive definite correlation matrix, and s k is the standard deviation for the random effects n ik . Let diag(s 1 , . . . , s K ) be a diagonal matrix with elements s i , the covariance matrix is thus S K =diag(s 1 , ...,s K )3R K 3diag(s 1 , ...,s K ). Here, s k captures trial-level heterogeneity in response to treatment k, and R K captures the within-study dependence among treatments. Based on the model in equation (2.3), the population-averaged (or marginal) treatment-specific event rate can be estimated as 
, RR kl = p k =p l , and RD kl = p k À p l for a pairwise comparison between treatments k and l (k 6 ¼ l).
Since improper prior distributions may lead to an improper posterior in some complex models [42] [43] [44] [45] , we selected minimally informative but proper priors. Specifically, we chose a weakly informative prior N(0, t 2 m ) for m k with t 2 m = 1000, and a Wishart prior for the precision matrix, that is, S À1 K ;W(V, n), where the degrees of freedom n = K, V is a known K 3 K matrix with diagonal elements equal to 1.0, and offdiagonal elements equal to 0.005. It turned out that the above prior corresponded to a 95% credible interval (CI) of 0.45-32.10 for the standard deviation parameters and a 95% CI of 21.00 to 1.00 for the correlation parameters, which is computed via simulations using the R function rWishart(). The Wishart distribution is the conjugate prior of the precision matrix of a multivariate normal random vector in Bayesian statistics, which facilitates the computation of the unstructured posterior covariance matrix.
We implemented our method within a fully Bayesian framework using Markov chain Monte Carlo (MCMC) methods with the WinBUGS software [46, 47] . Weakly informative priors were used and posterior samples were drawn using Gibbs and Metropolis-Hastings algorithms [48, 49] , with convergence assessed using trace plots, sample autocorrelations, and other standard convergence diagnostics [50, 51] . A generous burn-in period of 1,000,000 iterations was used, with 1,000,000 subsequent iterations retained for accurate posterior treatment effect estimates.
By borrowing information across multiple treatments, the MBHMM that we utilize reduces potential bias when missing is not completely at random, compared to a naive approach of estimating population-averaged treatment-specific event proportions or rates based solely on studies that used a particular treatment. For this Bayesian approach, we used the 95% posterior CIs to assess statistical significance (according to whether the CI included the null value) instead of p-values [52] . The corresponding WinBUGS code is presented in Appendix A.
Evaluation of different approaches
To investigate the performance of the proposed 'arm-based' MBHMM, we create two hypothetical NMA data sets under either a homogeneous RR or a homogeneous RD assumption. Each NMA includes 11 trials and 3 treatment arms. Because in a typical NMA most trials only compare a subset of all treatments of interest, we let two trials compare all three treatments, and three trials each comparing A and B, B and C, and A and C, respectively. The total numbers of patients are equal to 1000 for arm A, 2000 for arm B, and 500 for arm C in all trials. The response rates for arm A are assigned from a uniform distribution ranging from 0.10 to 0.40 in ascending order for the 11 trials. The corresponding numbers of responses for arm B and C in each trial are assigned based on a fixed RR or a fixed RD assumption. Specifically, the RR of B versus A is 1.50 and that of C versus A is 2.00 under the fixed RR assumption, and the RD of B versus A is 15% and that of C versus A is 25% under the fixed RD assumption. To simplify illustration, we ignore the random sampling error and assume the number of events is equal to the response rates multiplied by the total number of patients.
We analyzed the above two hypothetical data using four methods. The first is based on Cochran-Mantel-Haenszel procedure with estimates of the log OR and variance as discussed in Yusuf et al. (we refer to this as Peto's method) [53] . With this fixed effect method, inferences are based on the direct head-to-head pairwise comparisons. The second and third methods are the Lu and Ades' 'contrast-based' NMA method under either a homogeneous variance (i.e., the homogeneity of variance (HOM) model) or an unstructured heterogeneous variance assumption (i.e., the ID model) [27] . It combines the direct and indirect evidence, but it is not able to estimate the population-averaged treatment-specific event rates. The fourth is the 'arm-based' NMA method that we have proposed. By borrowing information across treatment arms, it is able to estimate the treatmentspecific event rates. The hypothetical data and the assumptions underlying these four methods are given in the web appendixes wTable 1 and wTable 2, respectively.
Results
Comparison of four methods for hypothetical data Table 1 presents the ORs based on the pairwise headto-head comparisons for each hypothetical trial. The Network meta-analysis of randomized clinical trials 249 difference between the mean ORs from the observed data versus the mean ORs from the full data illustrates the potential bias of summarizing treatment effects based only on trials with particular treatment arms, that is, the direct head-to-head comparisons. As evidenced by these two examples, the direction of bias can be either toward the null or away from the null, depending on the underlying data generating and missing data generating mechanisms, which limits the application and generalizability of methods based on direct head-to-head comparisons. For example, the true mean OR of B versus A under a fixed RR assumption is 1.85, as compared to the mean OR of 1.66 based on the available direct headto-head comparisons. The true mean OR of B versus A under a fixed RD assumption is 2.15, as compared to the mean OR of 2.45 based on the available direct head-to-head comparisons. Table 2 compares the population-averaged treatment-specific event rate estimates from the observed data versus that from the full data based on the new method. It shows that with this approach, estimates of the population-averaged treatment-specific event rates are nearly unbiased. In addition, the information loss due to missing data is mostly recovered as evidenced by the similarity of the length of the posterior CIs. Table 3 compares the relative treatment effect estimates for the four methods using the observed data (which assume that the grayed cells in web appendix wTable 1 are not available as in many NMAs) and the full data (which assume that each trial has three arms and there is no missing arms). Under the hypothetical data generating mechanisms, all four model assumptions are incorrect, and the 'true' ORs are not well defined. Thus, we choose the estimates 
Re-analyses of two NMAs recently published in The Lancet
Comparative efficacy and acceptability of 12 antidepressants
Cipriani et al. [6] comprehensively summarized results of 117 RCTs (25,928 participants) from 1991 to 2007 and compared 12 new-generation antidepressants in terms of efficacy and acceptability in acute-phase treatment of major depression. The main outcomes were the proportions of patients who responded to a treatment or discontinued the allocated treatment (dropped out). Response was defined as the total number of patients who had a reduction of at least 50% from baseline score at 8 weeks on the Hamilton depression rating scale (HDRS). Table 4 presents a summary of the efficacy results using the proposed method. A similar table that only cited ORs and 95% CIs was reported by Cipriani et al. [6] . The population-averaged treatment-specific response proportions are given in the diagonal entries in the table. These proportions range from 0.48 (95% CI: 0.41-0.55) for reboxetine (REB) to 0.62 (95% CI: 0.57-0.67) for mirtazapine (MIR). The upper and lower triangular panels report the RRs and RDs of all pairwise comparisons. Table 5 summarizes the treatment discontinuation proportions using the proposed method in the same format as the efficacy results. The population-averaged treatment-specific dropout rates (diagonal entries in the table) range from 0.21 for citalopram (CIT) (95% CI: 0.17-0.26) and escitalopram (ESC) (95% CI: 0.17-0.26) to 0.29 for REB (95% CI: 0.23-0.37), fluvoxamine (FVX) (95% CI: 0.23-0.37), and milnacipran (MIL) (95% CI: 0.21-0.37).
ESC and sertraline (SER) were more effective and more acceptable as measured by the proportion responding and discontinuing treatment. MIR and venlafaxine (VEN) had good efficacy but low acceptability as measured by the proportion discontinuing treatment. CIT had high acceptability but low efficacy. To visually compare the efficacy and acceptability of the 12 antidepressant drugs, Figure 1 presents the treatment-specific posterior medians of response and dropout proportions, with their 95% posterior CIs.
As compared to the results of Cipriani et al. [6] , for efficacy, we did not find significant differences between SER and paroxetine (PAR), nor between VEN and duloxetine (DUL). REB was only less effective than bupropion (BUP), ESC, MIR, SER, and VEN, but not other treatments. In terms of acceptability, both ESC and SER are better tolerated than FVX, PAR, REB, and VEN. In addition, SER is better tolerated than FLU. CIT is better tolerated than not only FVX and REB but also PAR. Finally, we did not find significant differences comparing BUP versus REB, and DUL versus ESC and SER. Figure 2 compares the ORs reported in Cipriani et al. [6] (y-axis) against the RRs estimated from our model (x-axis) of the 66 head-to-head comparisons of efficacy and treatment discontinuation. As expected, given how common the outcomes are, 81.1% (107/132) of the treatment effects are overestimated using the OR instead of the RR; only 18.9% (25/132) were underestimated. For efficacy, the overestimation can be as high as 57.4% (OR = 2.03 vs RR = 1.29 comparing MIR vs REB) while the underestimation is as high as 5.3% (OR = 1.00 vs RR = 0.95 comparing MIL and PAR); for acceptability, the overestimation goes up to 28.7% (OR = 0.62 vs RR = 0.87 comparing BUP vs REB) while the underestimation can be as large as 19.2% (OR = 0.87 vs RR = 0.73 comparing CIT and MIL). In addition, 7.6% (10/132) of the comparisons between ORs and RRs have opposite signs, for which both estimates are very close to the null (see red symbols in Figure 2 ). A direct comparison between the reported ORs in Cipriani et al. [6] and our marginal ORs is presented in the web appendix, and similar conclusions are shown.
Comparative efficacy and acceptability of antimanic drugs in acute mania
Cipriani et al. [7] comprehensively reviewed 68 RCTs (16,073 participants) from 1 January 1980 to Network meta-analysis of randomized clinical trials 251 Drugs are reported in alphabetical order. Diagonal panels are the population-averaged response rates (i.e., proportion of patients who had at least 50% reduction from the baseline score on Hamilton depression rating scale (HDRS)); upper triangular and lower triangular panels are the RRs and RDs of the first drug in alphabetical order compared with the second drug in alphabetical order, respectively. Drugs with higher response rate are more effective; RRs larger than 1.0 or positive RDs favor the first drug in alphabetical order. To obtain comparisons in the opposite direction, reciprocals should be taken for RR and opposite sign should be used for RD. Statistically significant results are given in bold. For all summaries, we report both the Bayesian posterior medians and the 95% credible intervals.
The diagonal grayed values refer to treatment-specific event rate estimates. *Comparisons statistically significant here but not in Cipriani et al. [6] or vice versa. The diagonal grayed values refer to treatment-specific event rate estimates. *Comparisons statistically significant here but not in Cipriani et al. [6] or vice versa.
Network meta-analysis of randomized clinical trials 253 25 November 2010, which compared antimanic drugs at therapeutic dose range for the treatment of acute mania in adults. The main outcomes were the mean change on mania rating scales and the proportion of patients who discontinued the assigned treatment at 3 weeks (dichotomous outcome for acceptability). The secondary outcome was response rate (response rate was defined as the proportion of the total number of patients who had a reduction of at least 50% on the total score between baseline and end point on a standardized rating scale for mania). Here, we only focus on the binary response for efficacy and the treatment discontinuation or dropout rate. Two treatments, gabapentin and asenapine, that were only included in one or two trials were excluded. Table 6 summarizes the efficacy results. The population-averaged treatment-specific response rates ranged from 0.22 (95% CI: 0.08-0.48) for topiramate (TOP) to 0.56 for olanzapine (OLA) (95% CI: 0.49-0.63) and haloperidol (HAL) (95% CI: 0.48-0.64). Compared to placebo (PLA), RRs and RDs are significant for all antimanic treatments, except lamotrigine (LAM) and TOP. In addition, all active treatments except LAM and ziprasidone (ZIP) are significantly more effective than TOP. Table 7 shows the results for acceptability (dropout). The population-averaged treatment-specific dropout proportions range from 0.30 for risperidone (RIS) (95% CI: 0.24-0.37) and OLA (95% CI: 0.25-0.36) to 0.48 for TOP (95% CI: 0.32-0.65). The upper and lower triangular panels report the RRs and RDs of all pairwise comparisons.
To visually compare the efficacy and acceptability of the 12 antimanic drugs, Figure 3 plots the treatment-specific posterior medians of the response and dropout proportions, with their 95% posterior CIs. The 95% CIs of LAM and TOP are extremely wide because they are studied in only three and five trials respectively, much fewer than the others. TOP is less effective and less well tolerated than PLA.
Our results differ from Cipriani et al. [7] in some aspects. For efficacy, we do not find significant differences when comparing HAL, RIS, and OLA with the other treatments, while in Cipriani et al.'s article [7] , HAL, RIS, and OLA showed significant efficacy compared with other treatments except PLA and TOP. For acceptability, except that OLA and RIS have significantly lower proportions of discontinuation compared to PLA, TOP, and ZIP, we do not find any other statistically significant head-to-head comparisons. In contrast, Cipriani et al. [7] found that OLA, RIS, and quetiapine (QUE) led to significantly fewer discontinuations than did lithium (LIT), LAM, PLA, and TOP. Figure 4 compares the ORs reported in Cipriani et al. [7] (y-axis) against the RRs estimated from our model (x-axis) of the 66 head-to-head comparisons for treatment discontinuation (acceptability) and the 11 comparisons with PLA for efficacy. Overall, 90.9% (70/77) of the treatment effects are overestimated, and 9.1% (7/77) of them are underestimated. Specifically, for efficacy, the overestimation is as high as 74.8% (OR = 1/0.40 = 2.50 vs RR = 1.43 comparing CAR vs PLA) while the underestimation is as high as 30.5% (OR = 1/1.30 = 0.77 vs RR =1/1.70 = 0.59 comparing TOP and PLA). For acceptability, the overestimation is as large as 54.3% (OR = 1/0.47 = 2.13 vs RR = 1.38 comparing LAM vs OLA), while the underestimation is as large as 18.0% (OR=1.05 vs RR=0.89 comparing LIT and PLA). In addition, 6.1% (4/66) of the comparisons between the RRs and the ORs for acceptability are in the opposite direction of the null (red plotting symbols in Figure 4) . A direct comparison between the reported ORs in Cipriani et al. [7] and our marginal ORs is presented in the web appendix, and similar conclusions are shown.
Discussion
NMA is increasingly utilized to synthesize direct and indirect evidence for different treatments. However, many current NMAs focus on treatment contrasts, in which one of the arms of each study is chosen as 'baseline'. Since different studies may have different 'baselines', as a consequence of changing standards of care or changes in the underlying risks of study populations (e.g., initial trial may include more severely ill patients), specifying a common distribution for 'baseline' groups is generally not Figure 2 . Comparison of the ORs versus the RRs for the 12 antidepressants. OR: odds ratio; RR: risk ratio. The dotted lines present the percentages of overestimation (bias away from the null) or underestimation (bias toward the null) of the treatment efficacy or acceptability if the ORs reported in Cipriani et al. [6] were misinterpreted as the RRs. The negative percentages denote underestimation and positive percentages denote overestimation.
Network meta-analysis of randomized clinical trials 255 Network meta-analysis of randomized clinical trials 257 interpretable. Although one may prefer to leave the 'baseline' treatment as a fixed, study-specific parameter with the argument that they are fundamentally different from each other. However, while we make a relatively strong assumption on exchangeability of the probability of events within each treatment group across studies, our model is valid under the MAR assumption. The CB Lu and Ades' approach is valid only under a MCAR assumption, as shown in a recent Agency for Healthcare Research and Quality (AHRQ) report (http://www.ncbi.nlm. nih.gov/books/NBK116689/pdf/TOC.pdf) and a corresponding technical report [54] . In addition, many current NMA methods only report the relative treatment effect on an OR scale [21] [22] [23] [24] [25] [26] [27] [28] [29] . Although they do offer valid statistical significance testing concerning the OR and can incorporate data from studies that only report relative treatment effects, without making strong assumptions on the event rate in a 'reference' group, they fail to estimate and report treatment-specific event rates, RDs, and RRs, which should be considered in making treatment recommendations. Although in some cases it is unfortunate that some people tend to misspecify the distribution for the 'reference' group and sometimes can lead to incorrect inference and interpretation, it should not construed to against our effort to estimate and report treatment-specific event rates. With the two comprehensive overviews, we illustrate how this novel AB Bayesian hierarchical model can be used to estimate these key statistics, and in some circumstances lead to different conclusions. For the two published NMAs [6, 7] , relatively high response proportions (up to 0.62) were observed. The differences between ORs and RRs that we illustrate can be explained in large part by the theoretical difference between the OR and the RR for common events [55] . The limitation of only reporting the ORs is discussed in detail in the web appendix. There is also a theoretical difference between the marginal treatment effects, averaged over all studies by our approach, and the conditional treatment effects reported for a typical NMA by the CB approaches such as used by Cipriani et al. [6, 7] . Marginal treatment effects are generally smaller than the conditional treatment effects estimated from random effects models [56] . Finally, our differing ORs and RRs may partially be the result of the potential difference between model assumptions (e.g., the assumed variance and correlation structure) and the potential bias using current CB models as illustrated in the hypothetical data analyses.
To compare the performance of the proposed AB versus current CB Bayesian hierarchical models, we create two hypothetical NMA data sets including 11 trials and 3 treatment arms under either a homogeneous RR or a homogeneous RD assumption, in which the full data sets (i.e., assuming each trial compares all treatment arms) are available to estimate the true parameters (see details in the web appendix). We found that the proposed AB NMA method outperformed the current CB NMA methods.
In addition to some common concerns of NMA [5, 10, 39] , there are some additional limitations for the proposed NMA approaches. First, to facilitate the estimation of treatment-specific populationaveraged event proportions, we assume that each study hypothetically compares all treatments, with unstudied arms being MAR conditional on the observed arms. Such models allow us to borrow information across multiple treatments within studies to reduce potential bias. However, it is plausible that investigators may have selected treatment arms on purpose based on the results of previous trials, which may lead to 'nonignorable missingness' and potentially bias our event rate estimation. In addition, to robustly estimate event rates for each treatment, it is very important to have adequate number of trials with adequate samples for each treatment in a NMA. Different model assumptions may lead to different results in poorly connected networks. Second, in this article, we only considered a saturated MBHMM with unstructured variance-covariance matrix. Although various model simplifications gave similar results (not presented), we did not perform analysis over all possible reduced models (e.g., models with equal variances and/or equal correlations Network meta-analysis of randomized clinical trials 259 among all treatments), a number of which may further improve statistical efficiency. Arguably, the unstructured variance-covariance matrix allows us to better summarize the evidence contained in the data without enforcing an artificial structure, such as equal variances or equal correlations. Third, in addition to the evaluation of heterogeneity of treatment effects, inconsistency is a major concern in NMA. Much ongoing debate over the value of NMA concerns the agreement between the direct and indirect evidence. In addition, inconsistency and its trade-off with heterogeneity can be very important when selecting the scale for NMA [57] . Achana et al. [58] have proposed an important method to adjust for baseline imbalance in order to possibly reduce heterogeneity and inconsistency for the CB methods. Some statistical methods have been proposed for identifying this disagreement when using CB approaches with the OR as the main effect measure [25, 40, [59] [60] [61] ; statistical methods for identifying and accounting for potential inconsistency based on our proposed models, formulated from the missing data perspective, await further development. Finally, in this article, we do not consider individual-level or study-level covariates, which have already been briefly discussed elsewhere [62, 63] .
In summary, we have proposed and implemented a novel AB multiple-treatments meta-analysis in a Bayesian framework, which is different than the methods used by Cipriani et al. in the two NMAs [6, 7] . With this AB approach, estimates of treatment-specific event rates or proportions, RDs, and RRs are provided. Using two hypothetical data sets, we show that our method provides more accurate estimates than the methods used by Cipriani et al. [6, 7] . Such differences could lead to different treatment recommendations.
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